REFILE-Teva sets final price terms for SFr1bn bond deal

July 21, 2016 9:45 AM

26 0

LONDON, July 21 (IFR) - Teva Pharmaceutical has set final price terms for a SFr1bn three-tranche bond issue to help fund its US$40.5bn acquisition of Actavis Generics, according to a lead bank.

The price for the SFr300m two-year tranche is set at a yield of 0.125%, the SFr350m six-year at mid-swaps plus 105bp, and the SFr350m nine-year tranche at mid-swaps plus 135bp.

Read more

To category page